| 摘要 |
The invention relates to an antitumoral pharmaceutical combination comprising cabazitaxel of formula: (see above formula) and prednisone or prednisolone, these two agents possibly being in base form, or in the form of a hydrate or a solvate, intended for treating metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
|
